Management of patients with lung cancer and poor performance status

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Patients who are able to care for themselves but are unable to perform most work-related activities are considered to have a poor performance status (PS). Individuals who fulfill these criteria constitute a significant proportion of all patients with lung cancer. Patients with lung cancer and a poor PS, irrespective of age, have an increased incidence of adverse effects with therapy and poorer outcomes. Thus, although these individuals must be treated differently, data on optimal approaches for these patients are lacking, because this cohort is underrepresented in conventional clinical trials due to enrollment restrictions. This article presents the available evidence on the treatment of this group of patients with lung cancer. Although patients with PS 2 have worse overall outcomes than those with good PS, a selected proportion may still benefit from standard therapy. Further trials are needed to identify optimal strategies to treat this group of patients with lung cancer.

Original languageEnglish (US)
Pages (from-to)1015-1025
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number7
DOIs
StatePublished - Jul 1 2014

Fingerprint

Lung Neoplasms
Therapeutics
Clinical Trials
Incidence

ASJC Scopus subject areas

  • Oncology

Cite this

Management of patients with lung cancer and poor performance status. / Gajra, Ajeet; Marr, Alissa S; Ganti, Apar Kishor P.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 12, No. 7, 01.07.2014, p. 1015-1025.

Research output: Contribution to journalArticle

@article{c56d9630d2144997831c9922bceba137,
title = "Management of patients with lung cancer and poor performance status",
abstract = "Patients who are able to care for themselves but are unable to perform most work-related activities are considered to have a poor performance status (PS). Individuals who fulfill these criteria constitute a significant proportion of all patients with lung cancer. Patients with lung cancer and a poor PS, irrespective of age, have an increased incidence of adverse effects with therapy and poorer outcomes. Thus, although these individuals must be treated differently, data on optimal approaches for these patients are lacking, because this cohort is underrepresented in conventional clinical trials due to enrollment restrictions. This article presents the available evidence on the treatment of this group of patients with lung cancer. Although patients with PS 2 have worse overall outcomes than those with good PS, a selected proportion may still benefit from standard therapy. Further trials are needed to identify optimal strategies to treat this group of patients with lung cancer.",
author = "Ajeet Gajra and Marr, {Alissa S} and Ganti, {Apar Kishor P}",
year = "2014",
month = "7",
day = "1",
doi = "10.6004/jnccn.2014.0098",
language = "English (US)",
volume = "12",
pages = "1015--1025",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "7",

}

TY - JOUR

T1 - Management of patients with lung cancer and poor performance status

AU - Gajra, Ajeet

AU - Marr, Alissa S

AU - Ganti, Apar Kishor P

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Patients who are able to care for themselves but are unable to perform most work-related activities are considered to have a poor performance status (PS). Individuals who fulfill these criteria constitute a significant proportion of all patients with lung cancer. Patients with lung cancer and a poor PS, irrespective of age, have an increased incidence of adverse effects with therapy and poorer outcomes. Thus, although these individuals must be treated differently, data on optimal approaches for these patients are lacking, because this cohort is underrepresented in conventional clinical trials due to enrollment restrictions. This article presents the available evidence on the treatment of this group of patients with lung cancer. Although patients with PS 2 have worse overall outcomes than those with good PS, a selected proportion may still benefit from standard therapy. Further trials are needed to identify optimal strategies to treat this group of patients with lung cancer.

AB - Patients who are able to care for themselves but are unable to perform most work-related activities are considered to have a poor performance status (PS). Individuals who fulfill these criteria constitute a significant proportion of all patients with lung cancer. Patients with lung cancer and a poor PS, irrespective of age, have an increased incidence of adverse effects with therapy and poorer outcomes. Thus, although these individuals must be treated differently, data on optimal approaches for these patients are lacking, because this cohort is underrepresented in conventional clinical trials due to enrollment restrictions. This article presents the available evidence on the treatment of this group of patients with lung cancer. Although patients with PS 2 have worse overall outcomes than those with good PS, a selected proportion may still benefit from standard therapy. Further trials are needed to identify optimal strategies to treat this group of patients with lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84903945876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903945876&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0098

DO - 10.6004/jnccn.2014.0098

M3 - Article

VL - 12

SP - 1015

EP - 1025

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 7

ER -